All Categories
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
For Women Over 50, AI Could Change Breast Cancer...
For women over 50, a breast cancer diagnosis often comes with a difficult and deeply personal question: Do you really need ch [...]
He Was Told He Needed Surgery for Cancer: A...
When Howard Wolinsky went in for a routine checkup in his mid-50s. He thought he was doing everything right. “I was just bein [...]
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized...
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]
ASCO to shine light on multimodal AI models: Plus,...
Dr. Lu will highlight recent work using specimens from the NRG B-20 trial, in which investigators applied multimodal AI appro [...]
Artera Secures CE Marking for Its AI Prostate and...
Dual regulatory milestones establish Artera as a global AI leader in precision oncology SAN FRANCISCO, April 21, 2026— Artera [...]
Artera Product Webinar April 2026
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]
Balancing survival and quality of life: The evolving role...
Traditional oncology metrics have long measured success in survival curves and hazard ratios, not in days spent comfortably w [...]